MediWound Reports Fourth Quarter and Full-Year 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street closes lower as oil prices jump, indexes notch monthly gains
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- BofA turns S&P 500 signals from red to yellow: What to buy now
MediWound (MDWD) Tops Q4 EPS by 5c, Revenues Beat
February 25, 2021 7:27 AM ESTMediWound (NASDAQ: MDWD) reported Q4 EPS of ($0.06), $0.05 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $6.67 million versus the consensus estimate of $5.59 million.
Fourth Quarter and Full-Year 2020 Business Highlights:
U.S. Food and Drug Administration (FDA) accepted for review the Companys Biologics License Application (BLA) for NexoBrid® and assigned a Prescription Drug User Fee Act (PDUFA) target date of June 29, 2021.BARDA initiated the procurement of NexoBrid for emergency stockpile, valued at $16.5 million, with first deliveries accepted by BARDA in the third and fourth quarters of 2020, with... More